<?xml version="1.0" encoding="utf-8"?>
			<journal>
			<title>Journal of Cardio-Thoracic Medicine</title>
			<title_fa></title_fa>
			<short_title></short_title>
			<subject>Medical Sciences</subject>
			<web_url>https://jctm.mums.ac.ir/</web_url>
			<journal_hbi_system_id>0</journal_hbi_system_id>
			<journal_hbi_system_user></journal_hbi_system_user>
			<journal_id_issn>2345-2447</journal_id_issn>
			<journal_id_issn_online>2322-5750</journal_id_issn_online>
			<journal_id_pii></journal_id_pii>
			<journal_id_doi></journal_id_doi>
			<journal_id_iranmedex></journal_id_iranmedex>
			<journal_id_magiran></journal_id_magiran>
			<journal_id_sid></journal_id_sid>
			<journal_id_nlai></journal_id_nlai>
			<journal_id_science></journal_id_science>
			<language>en</language>
			<pubdate>
				<type>jalali</type>
				<year>0</year>
				<month>0</month>
				<day>1</day>
			</pubdate>
			<pubdate>
				<type>gregorian</type>
				<year>2026</year>
				<month>3</month>
				<day>1</day>
			</pubdate>
			<volume>14</volume>
			<number>1</number>
			<publish_type>online</publish_type>
			<publish_edition>1</publish_edition>
			<article_type>fulltext</article_type>
			<articleset><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>A Game Changer for Low and Middle Income Countries: Del Nido Cardioplegia for Adult Cardiac Surgery – A Tertiary Care Experience</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Original Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Introduction: Del Nido Cardioplegia (DNC) offers prolonged myocardial protection through a single-dose approach.Methods: This retrospective study involved 175 adult patients from five surgical groups (DVR, MIS‑MVR, MVR via sternotomy, AVR, congenital repairs). Statistical analysis was conducted using SPSS v25. Quantitative variables were assessed using t‑tests /Mann–Whitney U tests, while categorical variables were analyzed using chi‑square/Fisher’s exact tests. Significant differences (p&lt;0.05) in ACC and CPB durations were observed across the groups.Results: The return to spontaneous sinus rhythm ranged from 90% to 100% among the groups. Significant variations in ACC and cardiopulmonary bypass (CPB) times were noted (p&lt;0.05). Single‑dose DNC proved to be effective in all cases.Conclusion: DNC demonstrates safety and efficiency in low- and middle-income country (LMIC) settings.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>Cardioplegia, Cardiac surgical procedures, Cardiopulmonary Bypass, Del Nido Solution, Low- and Middle‑Income Countries, Myocardial protection</keyword>
				<start_page>1629</start_page>
				<end_page>1637</end_page>
				<web_url>https://jctm.mums.ac.ir/article_27340.html</web_url>
			<author_list><author>
				<first_name>Parth</first_name>
				<middle_name></middle_name>
				<last_name>Vaghela</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>parth_vaghela911@yahoo.com</email>
				<code>120045</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Department of Cardiothoracic and Vascular Surgery, GCS Medical College, Hospital and Research Centre, Ahmedabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Maya</first_name>
				<middle_name></middle_name>
				<last_name>Damor</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>drmayadamor25@yahoo.com</email>
				<code>120046</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Anesthesia, GCS Medical College, Hospital and Research Center, Ahmedabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Jishna</first_name>
				<middle_name></middle_name>
				<last_name>Vaghela</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>jisnavaghela@gmail.com</email>
				<code>120047</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Orthodontics and Dentofacial Orthopedics, College of Dental Sciences, Amargarh, Bhavnagar, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>Outcome of Fresh Frozen Plasma Versus Albumin in Priming Solution of Extracorporeal Circuit in Neonatal Cardiac Surgery: A Prospective Comparative Observational Study</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Original Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Introduction: In neonatal cardiac surgery, the choice of cardiopulmonary bypass (CPB) priming fluid is crucial. Fresh frozen plasma (FFP) provides essential coagulation factors that can help reduce bleeding, while albumin helps maintain oncotic pressure and may protect renal function. This study aimed to compare the outcomes of FFP- based priming versus albumin-based priming.Methods: This prospective observational study was conducted from June 2022 to October 2024 and involved 100 neonates (weighing ≤5 kg) undergoing CPB. Patients were alternately assigned to receive 10 mL/kg of FFP (n = 50) or 5% albumin (n = 50) in the priming fluid. Outcomes included bleeding, transfusion requirements, hemodynamic stability, renal function, mechanical ventilation duration, intensive care unit (ICU) stay, hospital stay, and mortality. Data were analyzed using t tests and chi-square tests.Results: Baseline characteristics were similar between the two groups. Chest drain output and total blood product use were comparable (p &gt; 0.05), except the FFP group required more albumin transfusion at 24 hours (p = 0.031). Hemodynamics were mostly similar, although mean arterial pressure was slightly higher in the albumin group at 48 hours (p = 0.040). Serum creatinine was significantly higher in the FFP group preoperatively and at 24–48 hours postoperatively (p ≈ 0.02–0.03), while urine output was similar. Duration of ventilation, ICU stay, hospital stay, and mortality showed no difference.Conclusion: Albumin priming may offer modest renal protection and reduce donor exposure. FFP remains an acceptable alternative. Larger randomized trials are required.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>congenital heart disease, Extracorporeal Circulation, Fresh Frozen Plasma, Heart-Lung Machine</keyword>
				<start_page>1638</start_page>
				<end_page>1645</end_page>
				<web_url>https://jctm.mums.ac.ir/article_27293.html</web_url>
			<author_list><author>
				<first_name>Shreya</first_name>
				<middle_name></middle_name>
				<last_name>Singh</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>shreya1611s@gmail.com</email>
				<code>119836</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Cardiac Anesthesia, U.N.Mehta Institute of Cardiology and Research Center, Ahmadabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Mrugesh</first_name>
				<middle_name></middle_name>
				<last_name>Prajapati</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>drmrugesh_2606@yahoo.com</email>
				<code>119837</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Department of Cardiac Anesthesia, U.N.Mehta Institute of Cardiology and Research Center, Ahmadabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Kaushal</first_name>
				<middle_name></middle_name>
				<last_name>Patel</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>kapps1991@gmail.com</email>
				<code>119838</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Cardiac Anesthesia, U.N.Mehta Institute of Cardiology and Research Center, Ahmadabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Gowtham</first_name>
				<middle_name></middle_name>
				<last_name>Thakut</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>gowtham887@gmail.com</email>
				<code>119839</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Cardio Vascular and Thoracic Surgery, U.N.Mehta Institute of Cardiology and Research Center, Ahmadabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Priyanga</first_name>
				<middle_name></middle_name>
				<last_name>Murugesan</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>priyangamurugesan5@gmail.com</email>
				<code>119840</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Cardiac Anesthesia, U.N.Mehta Institute of Cardiology and Research Center, Ahmadabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Ravina</first_name>
				<middle_name></middle_name>
				<last_name>Modi</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>ravinam@unmicrc.org</email>
				<code>119841</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Cardiac Anesthesia, U.N.Mehta Institute of Cardiology and Research Center, Ahmadabad, Gujarat, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>Pulmonary Complications and Systemic Abnormalities in Post-COVID-19 Patients: A 3-Month</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Original Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Introduction: The coronavirus disease 2019(COVID-19) pandemic has had significant acute and long-term health impacts. Persistent pulmonary and systemic complications after recovery remain inadequately studied. This cohort study aimed to assess chronic respiratory and systemic abnormalities in patients three months post-COVID-19 recovery.Methods: We evaluated 100 patients more than three months after recovery. Assessments included spirometry, high-resolution computed tomography (HRCT), arterial blood gas (ABG) analysis, and laboratory tests of inflammatory and hematologic parameters. Patients with preexisting lung disease or those to perform spirometry were excluded. Data were analyzed using SPSS version 27.Results: The cohort consisted of 100 patients (mean age 49.8 ± 15.1 years; 50 males, 50 females). While clinical symptoms significantly decreased after three months, cough and dyspnea persisted in a notable proportion. Of the patients, 59.8% were managed as outpatients, 18.5% were hospitalized in general wards, and 21.7% required intensive care unit (ICU) admission. Spirometry revealed ongoing pulmonary dysfunction across obstructive, restrictive, and mixed patterns, with significantly reduced predicted forced expiratory volume in 1 second (FEV₁) and Forced Vital Capacity (FVC). The FEV₁/FVC ratio was notably decreased in obstructive and mixed groups, indicating persistent airflow limitation. Lung Computed Tomography (CT) scan showed significant resolution of ground-glass opacities (80.9% to 18.8%) and consolidation (19.1% to 3.5%). However, fibrotic-like changes, including septal thickening, persisted or slightly increased (21.3% to 32.9%). Other structural abnormalities were uncommon and largely unchanged.Conclusion: Most patients showed symptomatic improvement by three months, but a significant subset continued to exhibit respiratory dysfunction and structural lung alterations. These findings highlight the importance of long-term clinical and radiological monitoring of post-COVID-19 patients and suggest broader implications for managing post-viral respiratory sequelae.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>COVID-19, Post-COVID-19, Follow up, Pulmonary, Respiratory Function Tests</keyword>
				<start_page>1646</start_page>
				<end_page>1655</end_page>
				<web_url>https://jctm.mums.ac.ir/article_27369.html</web_url>
			<author_list><author>
				<first_name>Farzaneh</first_name>
				<middle_name></middle_name>
				<last_name>Akbari</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>akbari.f.89@gmail.com</email>
				<code>120200</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Zahra</first_name>
				<middle_name></middle_name>
				<last_name>Javid Arabshahi</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>javidarabshahiz@mums.ac.ir</email>
				<code>120201</code>
				<coreauthor>No</coreauthor>
				<affiliation>Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Sepideh</first_name>
				<middle_name></middle_name>
				<last_name>Hejazi</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>hejazis@mums.ac.ir</email>
				<code>120202</code>
				<coreauthor>No</coreauthor>
				<affiliation>Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Fariba</first_name>
				<middle_name></middle_name>
				<last_name>Rezaeetalab</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>rezaitalabf@mums.ac.ir</email>
				<code>120203</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Arezoo</first_name>
				<middle_name></middle_name>
				<last_name>Faridzadeh</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>faridzadeha2@mums.ac.ir</email>
				<code>120204</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Immunology and Allergy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Elham</first_name>
				<middle_name></middle_name>
				<last_name>Shaarbaf Eidaghi</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>sharbafe3@mums.ac.ir</email>
				<code>120205</code>
				<coreauthor>No</coreauthor>
				<affiliation>Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Mahnaz</first_name>
				<middle_name></middle_name>
				<last_name>Mozdourian</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>mozdorianmh@mums.ac.ir</email>
				<code>120206</code>
				<coreauthor>No</coreauthor>
				<affiliation>Lung Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>Utility of Forced Oscillation Technique in Detecting Obstruction in Asthma and the Significance of ‘Isolated Increase in R5-R20’ (II R5-R20)</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Original Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Introduction &amp; objective : The objective of this retrospective observational study was to investigate the role of forced oscillometry in detecting airway obstruction in asthma and to compare its sensitivity to that of spirometry in detecting airway obstruction.Method: The retrospective observational study was conducted in the Pulmonary Medicine Department of a secondary hospital in South India. Data from diagnosed cases of asthma from  October 1, 2024, to March 31, 2025, were collected and analyzed to determine the effectiveness of forced oscillometry in detecting airway obstruction in asthma compared to spirometry. Diagnosis of asthma was made by the treating pulmonologist based on history, examination, and investigations. The cohort included patients over eighteen years of age who underwent both oscillometry and spirometry. Patients who only had one of the tests done were excluded from the study. Asthma-COPD overlap syndromes were also excluded.Results: The total number of patients in the cohort was 182 with a mean age of 48.5 years. Spirometry showed obstruction in 36.8% of diagnosed asthma cases, while forced oscillometry detected obstruction in 69.7% of cases (p &lt; 0.0001, 95% CI 20%–46%, RR-1.89). When both spirometry and oscillometry were combined, the sensitivity for detecting underlying airway obstruction increased to 80.8% (n = 147). Isolated increase in R5-R20 (II R5-R20) was observed in 36.81% of the cohort, whit this phenomenon seen in 52.5% of cases where oscillometry was more successful than spirometry.Conclusion: Oscillometry is more sensitive than spirometry in detecting airway obstruction in asthmatics. Using both methodsIt for evaluation increases sensitivity. ‘II R5-R20’ is defined as an increase in R5-R20 with a normal R5 and is the most sensitive parameter for detecting airway disease in asthmatics. It may detect the early changes in airway resistance, making it useful  for identifying airway obstruction at an earlier stage.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>Asthma, forced oscillation technique, obstructive airway disease, oscillometry</keyword>
				<start_page>1656</start_page>
				<end_page>1661</end_page>
				<web_url>https://jctm.mums.ac.ir/article_27341.html</web_url>
			<author_list><author>
				<first_name>Akhil</first_name>
				<middle_name></middle_name>
				<last_name>Paul</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>akhil_pauli@yahoo.com</email>
				<code>120048</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Head of the Department of Pulmonary and Sleep Medicine, MOSC Medical Mission Hospital, Thrissur, Kerala, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>VKORC1 and CYP2C9 Genetic Variants Coumarin Response in the Mestizo-Mexican Population</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Original Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Introduction: Polymorphisms in the genetic variations of vitamin K epoxide reductase complex subunit 1 (VKORC1) and Cytochrome P450 subfamily IIC polypeptide 9 (CYP2C9) have been shown to cause variability in anticoagulant response across various ethnic groups. In the Mestizo-Mexican population, with their Amerindian-European and African-Asiatic ancestral origins, the response is expected to differ as well. This study aims to evaluate the anticoagulant response to coumarin in Mestizo-Mexican patients with mechanical heart valve prostheses.Method: DNA was extracted from blood samples using a commercial genomic DNA purification kit. The polymorphisms rs1799853 CT in the CYP2C9*2 gene and rs9923231VKORC1-G1639A gene were determined using real-time PCR. All patients initially received a dose of 8 mg/day of coumarin, which was adjusted on the second day based on international normalized ratio (INR) levels until reaching a result of 2.5-3.5.Results : Seventy-six patients with an average age of 58±11 years were undergoing mitral (n=44) and aortic (n=32) valve replacement. Patients carrying GG haplotypes in the rs9923231VKORC1-G1639A gene variant required a significantly higher coumarin dose to reach the therapeutic range compared to those with GA and AA haplotypes (p=0.001). The rs1799853 polymorphism of the CYP2C9*2 A/C gene showed no significant differences between AA, AC, and CC haplotypes (p&gt;0.05).Conclusion : In the Mestizo-Mexican population, individuals carrying the rs9923231 VKORC1 gene with GG haplotypes exhibited a hyporeactive anticoagulant response compared to those with GA and AA haplotypes, which showed normal and hyperreactive responses, respectively. There were no significant differences in the response of the CYP2C9*2 haplotypes AC carriers.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>Coumarin anticoagulation, Mestizo-Mexican population, VIKORC1 &amp; CYP2C9*2 genetic variants</keyword>
				<start_page>1662</start_page>
				<end_page>1667</end_page>
				<web_url>https://jctm.mums.ac.ir/article_27173.html</web_url>
			<author_list><author>
				<first_name>José</first_name>
				<middle_name>Luis</middle_name>
				<last_name>Aceves Chimal</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>aceves996@hotmail.com</email>
				<code>119356</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Cardiothoracic Surgeon, Cardiovascular Department, CMN 20 de Noviembre, ISSSTE. México City.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Guillermo</first_name>
				<middle_name></middle_name>
				<last_name>Díaz Quiroz</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>gdiazquiroz@yahoo.com.mx</email>
				<code>119357</code>
				<coreauthor>No</coreauthor>
				<affiliation>Cardiothoracic Surgeon, Cardiovascular Department, CMN 20 de Noviembre, ISSSTE. México City.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Mónica</first_name>
				<middle_name></middle_name>
				<last_name>Escamilla Tilch</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>monica.escamilla@issste.gob.mx</email>
				<code>119358</code>
				<coreauthor>No</coreauthor>
				<affiliation>Science Research Doctor, Biomedical Research Department, CMN 20 de Noviembre ISSSTE, México City.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Silvia</first_name>
				<middle_name></middle_name>
				<last_name>Cortes Martínez</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>silvia1830@hotmail.com</email>
				<code>119359</code>
				<coreauthor>No</coreauthor>
				<affiliation>Pharmacobiological Chemistryc, Hormons Laboratory, CMN 20 de Noviembre ISSSTE, México City.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>Immunomodulatory Therapies in Hypersensitivity Pneumonitis: A Comprehensive Review</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Review Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease (ILD) caused by repeated inhalation of environmental antigens. Clinically, it varies widely from temporary, reversible inflammation to long-term, progressive fibrosis. The primary approach in managing HP remains identifying and removing exposure to the causative antigens, and treatment often requires corticosteroids in acute or severe cases. However, many patients, especially those with chronic or fibrotic HP (cHP/fHP), may progress despite corticosteroid treatment, highlighting the urgent need for other effective and tolerable immunomodulatory and antifibrotic therapies. This review discusses the current and emerging treatments for HP, focusing on the rationale, clinical data, and practical aspects of traditional immunosuppressants such as corticosteroids, mycophenolate mofetil, and azathioprine, as well as new biologics and antifibrotic drugs that are transforming the treatment landscape for this complex disease.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>Antifibrotic, hypersensitivity pneumonitis, Immunomodulation, Interstitial lung disease, Rituximab</keyword>
				<start_page>1668</start_page>
				<end_page>1675</end_page>
				<web_url>https://jctm.mums.ac.ir/article_26916.html</web_url>
			<author_list><author>
				<first_name>Sanket</first_name>
				<middle_name></middle_name>
				<last_name>Joshi</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>sanketjoshi1994@gmail.com</email>
				<code>118174</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Pulmonary Medicine, PGIMSR-ESIC Model Hospital, New Delhi, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Dipti</first_name>
				<middle_name></middle_name>
				<last_name>Gothi</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>diptigothi@gmail.com</email>
				<code>118173</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Department of Pulmonary Medicine, PGIMSR-ESIC Model Hospital, New Delhi, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Manika</first_name>
				<middle_name></middle_name>
				<last_name>Sachdeva</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>manika.sachdeva1992@gmail.com</email>
				<code>118175</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Pulmonary Medicine, Mata Chanan Devi Hospital, New Delhi, India.</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article>
			</articleset>
			</journal>